The Share

The Diamyd Medical share is traded on Nasdaq First North Growth Market (ticker : DMYD B). ISIN code: SE0005162880.

About Nasdaq First North Growth Market

Nasdaq First North Growth Market is an alternative marketplace operated by an exchange within the Nasdaq Group. Companies on Nasdaq First North Growth Market are not subject to the same rules as companies on the regulated main market. Instead they are subject to a less extensive set of rules and regulations adjusted to small growth companies. The risk in investing in a company on Nasdaq First North Growth Market may therefore be higher than investing in a company on the main market. All companies with shares traded on Nasdaq First North Growth Market have a Certified Adviser who monitors that the rules are followed. The Exchange approves the application for admission to trading.

Certified Adviser at Nasdaq First North Growth Market

FNCA Sweden AB, Humlegårdsgatan 5, Box 5807, SE-102 48 Stockholm. Tel: 08-528 00 399, E-mail: info@fnca.se.

Analysts

Analysts following Diamyd Medical:
Ludvig Svensson, Penser Access by Carnegie, Tel: +46 8 463 80 00. Penser Access by Carnegie

Annual Report

  November 29, 2023

Company Presentation

 October 9, 2024
  Year-End Report 23/24, October 9, 2024
The year has been characterized by a significant breakthrough in our discussions with the U.S. FDA. A major highlight of the year was our decisive step towards an accelerated approval pathway in the United States for Diamyd®. This strategy was bolstered by the positive outcome of our recent FDA discussions, where the Agency acknowledged that C-peptide, a marker for endogenous insulin production, could serve as a surrogate endpoint reasonably...
DIAGNODE-3 stands as the only ongoing Phase 3 trial worldwide for a disease-modifying therapy in Type 1 Diabetes, placing Diamyd Medical at the forefront of innovative treatments.
Ulf Hannelius, President and CEO

Calendar

  
Data pager
Data pager
12
November 14, 2024
Annual Report
Annual Report 2023/2024
November 14, 2024
Live broadcast
November 28, 2024
Småbolagsdag hos Carnegie
December 5, 2024
Annual General Meeting
Annual General Meeting 2023/2024
 

We are dedicated to finding a cure for autoimmune diabetes through pharmaceutical development and investments in medical and stem cell technologies

 

Ten largest shareholders as of August 31, 2024

ShareholderA SharesB SharesCapital %Votes %
Avanza Pension 11 954 656 11.99 9.50
Lindkvist, Bertil 8 680 000 8.70 6.90
Nordnet Pension 5 733 757 5.75 4.56
Essen-Möller, Anders * 815 793 3 117 040 3.94 8.96
Essen-Möller, Maria-Teresa 400 000 963 998 1.37 3.95
Konstruktions o Försäljningsaktiebolag 906 250 0.91 0.72
Swedbank Försäkring AB 899 969 0.90 0.72
Esssen-Möller, Martin 400 000 278 436 0.68 3.40
Essen-Möller, Jon 440 000 205 247 0.65 3.66
Hillborg, Erika 440 000 163 000 0.60 3.63
Remaining shareholders 400 000 63 924 832 64.50 54.00
Total 2 895 793 96 827 185 100.0 100.0

Order GAD for preclinical research

GAD PRODUCTS